Last reviewed · How we verify
GM2-KLH vaccine
GM2-KLH vaccine stimulates the immune system to recognize and attack cancer cells expressing the GM2 ganglioside antigen on their surface.
GM2-KLH vaccine stimulates the immune system to recognize and attack cancer cells expressing the GM2 ganglioside antigen on their surface. Used for Melanoma (adjuvant setting), Ovarian cancer.
At a glance
| Generic name | GM2-KLH vaccine |
|---|---|
| Sponsor | European Organisation for Research and Treatment of Cancer - EORTC |
| Drug class | Cancer vaccine |
| Target | GM2 ganglioside |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The vaccine consists of the GM2 ganglioside (a tumor-associated carbohydrate antigen) conjugated to keyhole limpet hemocyanin (KLH) carrier protein. This conjugate is designed to elicit a humoral and cellular immune response against GM2-expressing tumors, particularly melanoma and other cancers. The immune system is trained to produce antibodies and T-cell responses that target and eliminate cancer cells bearing this antigen.
Approved indications
- Melanoma (adjuvant setting)
- Ovarian cancer
Common side effects
- Injection site reactions (erythema, induration, pain)
- Fever
- Fatigue
- Myalgia
Key clinical trials
- Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free (PHASE2)
- Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission (PHASE1)
- Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence (NA)
- Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease (PHASE1)
- Vaccine Therapy in Treating Patients With Primary Stage II Melanoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GM2-KLH vaccine CI brief — competitive landscape report
- GM2-KLH vaccine updates RSS · CI watch RSS
- European Organisation for Research and Treatment of Cancer - EORTC portfolio CI